NCT05078580View on ClinicalTrials.gov

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Hepatic Impairment
Interventions
DRUG

Iptacopan

Single oral dose of iptacopan 200 mg oral capsules

DRUG

Iptacopan

Single oral dose of iptacopan 200 mg oral capsules

DRUG

Iptacopan

Single oral dose of Iptacopan 200 mg oral capsules

DRUG

Iptacopan

Single oral dose of Iptacopan 200 mg oral capsules

Trial Locations (1)

78215

Novartis Investigative Site, San Antonio

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY